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Key questions
What is already known about this subject?
 ► Many existing studies have looked at the prognostic 
value of a zero calcium score in asymptomatic study 
populations which have different prior probabilities 
of risk of major adverse cardiac event compared 
with symptomatic patient populations.
What does this study add?
 ► This study has the advantage of being a prospec-
tive study and looks at the medium-term prognosis 
of the symptomatic patient population with a zero 
calcium score.
How might this impact on clinical practice?
 ► The discovery of underlying coronary artery dis-
ease in those with zero calcium scores highlights 
the advantages of using CT coronary angiography 
in all subjects rather than having calcium scoring 
as a gatekeeper, as was the case in the previous 
version of the National Institute for Health and Care 
Excellence CG95 guideline.
ABSTRACT
Objectives To estimate the prevalence of non-calcified 
coronary artery disease (CAD) in patients with suspected 
stable angina and a zero coronary artery calcification 
(CAC) score, and to assess the prognostic significance of a 
zero CAC in these symptomatic patients.
Methods In this prospective cohort study, consecutive 
patients with stable chest pain underwent CAC scoring 
± CT coronary angiography (CTCA) as part of routine 
clinical care at a single tertiary centre over 7 years. Major 
adverse cardiac event (MACE) was defined as cardiac 
death, non-fatal myocardial infarction and/or non-elective 
revascularisation.
Results A total of 915 of 1753 (52.2%) patients (mean 
age 56.8 ± 12.0 years; 46.2% male) had a zero CAC 
score. Of the 751 (82.1%) patients with a zero CAC in 
whom CTCA was performed, 674 (89.7%) had normal 
coronary arteries, 63 (8.4%) had non-calcified CAD with 
< 50% stenosis and 14 (1.9%) had ≥ 50% stenosis in at 
least one coronary artery. The negative predictive value 
of a zero CAC for excluding a ≥ 50% CTCA stenosis was 
98.1%. Over a median follow-up period of 2.2 years 
(range 1.0–7.0 years), the absolute annualised rates of 
MACE were as follows: zero CAC 1.9 per 1000 person-
years and non-zero CAC 7.4 per 1000 person-years (HR 
3.8, p = 0.009). However, after adjusting for age, gender 
and cardiovascular risk factors using a multivariable Cox 
proportional hazards model, there was no statistically 
significant difference in the risk of MACE between the two 
patient cohorts (p = 0.19). After adjusting for age, gender 
and cardiovascular risk factors, the HR for all-cause 
mortality among the zero CAC cohort vers non-zero CAC 
was 2.1 (p = 0.27).
Conclusion A zero CAC score in patients undergoing CT 
scanning for suspected stable angina has a high negative 
predictive value for the exclusion of obstructive CAD and is 
associated with a good medium-term prognosis.
IntROduCtIOn
Coronary artery calcification (CAC) is a 
well-established marker of future cardiovas-
cular risk.1 Cardiac CT is widely used for the 
evaluation of stable coronary artery disease 
(CAD) due to it being a non-invasive, cost-ef-
fective and highly sensitive technique.2 CT 
calcium scoring detects and quantifies CAC 
and coronary CT coronary angiography 
(CTCA) allows for detailed anatomical eval-
uation of luminal stenosis secondary to both 
calcified and non-calcified atherosclerotic 
plaques.2
The absence of CAC (defined as a zero 
CAC score on CT) in asymptomatic individ-
uals is associated with a very low incidence 
of cardiovascular events over a 15-year 
follow-up.3 However, 1%–2% of symptom-
atic patients with chest pain, and a zero CAC 
score, have non-calcified coronary artery 
atherosclerosis.4 5 The long-term prognosis of 
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In November 2016, the UK’s National Institute for 
Health and Care Excellence’s (NICE) Clinical Guideline 
95 for the evaluation of patients with stable chest pain 
was issued as an update of their own 2010 Guideline.2 7 
The update recommended the removal of CT calcium 
scoring from the investigation algorithm on the basis 
that a zero CAC score may still be associated with signif-
icant underlying CAD, particularly non-calcified plaque, 
instead suggesting CTCA for all patients presenting with 
suspected angina.
Therefore, the objective of the study was to estimate the 
prevalence of non-calcified CAD in patients presenting 
with stable angina and a zero CAC score undergoing CT 
scanning in our centre. The secondary objectives were to 
compare incidence rates of major adverse cardiac events 
(MACEs), and all-cause mortality, in patients with a zero 
CAC versus a non-zero CAC score.
MetHOds
study design
In this prospective study, consecutive patients with a 
suspected new diagnosis of stable angina underwent CAC 
scoring ± CT coronary angiography (CTCA) as part of 
routine clinical care at Addenbrooke’s Hospital from 
November 2009 to October 2016. This was a service eval-
uation audit and it was approved by the hospital’s audit 
committee. Patients were excluded from the study if they 
were asymptomatic, had prior diagnosis of CAD, myocar-
dial infarction, percutaneous coronary intervention or 
coronary artery bypass grafting surgery. Patients referred 
for a cardiac CT scan for non-coronary indications such 
as arrhythmias, aortic valve and pericardial evaluations 
were excluded.
Clinical data were obtained from the hospital elec-
tronic patient record system. Hypertension was defined 
by a physician diagnosis of hypertension or the use of 
anti-hypertensive medications. Diabetes was defined by a 
physician diagnosis of diabetes or the use of anti-diabetic 
medications. Obesity was defined by a body mass index 
of 30 or greater. A positive smoking history was defined 
by the patient either being a current smoker (being an 
active smoker at the time of scan) or being an ex-smoker. 
A family history of premature CAD was defined as any 
first-degree relative with a history of relevant heart 
disease before age 60 or based on having a recorded 
family history of CAD in the patient record.
Ct imaging
Imaging was performed using a Siemens Flash 64×2-slice 
dual source CT scanner as per standard clinical proto-
cols. CAC scoring was performed using the Agatston 
method8 with Siemens SyngoVia analysis software V.VB9 
and V.VB10. Prior to CTCA imaging, intravenous meto-
prolol (5–20 mg) and sublingual glyceryl trinitrate (two 
sprays, 400 μg) were administered to all patients without 
contraindication. Intravenous contrast (70 mL Omni-
paque 350) was administered at 6 mL/second followed 
by 40 mL 0.9% saline flush. CTCA images were acquired 
with prospective ECG gating (70%), high-pitch single 
heart beat acquisition, retrospective mode or a combina-
tion as needed to obtain diagnostic image quality. Tube 
current was 150–300 mA and voltage 80–100 kV. CAC 
scanning and CTCA were performed on the same day. 
All CT scans were reported jointly by accredited cardiac 
radiologists and cardiologists. The severity of non-calci-
fied CAD on CTCA was graded as follows: normal coro-
nary arteries, non-obstructive (at least one <50% luminal 
diameter stenosis) and obstructive (at least one ≥50% 
luminal diameter stenosis).
Patient follow-up
Patients were followed up prospectively using the hospital 
electronic patient record system.
The endpoint, MACE, was defined as cardiac death, 
non-fatal myocardial infarction and/or non-elective 
revascularisation. Additionally, the incidence of all-cause 
mortality was evaluated. Revascularisation was defined as 
percutaneous coronary intervention or coronary artery 
bypass grafting surgery. A diagnosis of myocardial infarc-
tion was verified by a cardiologist.
statistical analysis
Continuous variables are presented as mean±SD or 
median and IQR, and categorical variables as counts 
with proportions. Comparison of between-group contin-
uous variables was performed using the unpaired t-test, 
whereas the Pearson χ2, two-tailed test was used for 
comparison of categorical variables.
A survival analysis was conducted with individual 
subject time-to-MACE using the Kaplan-Meier method, 
with curves representing MACE-free survival according 
to zero CAC or non-zero CAC. Annualised rates of MACE 
and all-cause mortality were estimated by dividing the 
number of events by the number of person-years at risk.
HR and 95% CIs were calculated with the Cox propor-
tional hazards regression model using zero CAC as the 
reference group. Three models were constructed: Model 
1: unadjusted, univariable analysis; Model 2: multivariable 
analysis adjusting for age and gender; Model 3: multivari-
able analysis adjusting for age, gender and cardiovascular 
risk factors (hypertension, diabetes, obesity, smoking 
history and family history).
All statistical analyses were performed using IBM SPSS 
Statistics for Macintosh, V.25.0. A two-tailed p value of 
<0.05 was considered statistically significant.
Results
Characteristics of study cohort
Over a 7-year period, 2253 patients underwent cardiac 
CT imaging at our institution. In all, 500 patients were 
excluded from the study cohort as they underwent 
imaging for indications other than investigation of 
chest pain, or because of a non-diagnostic calcium scan. 
Therefore, 1753 patients with symptomatic chest pain 
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Figure 1 Study flow chart. The values in parentheses represent the numbers of patients in each part of the study. The 
percentages in the lowest boxes represent the fraction of patients in each disease category. CAC, coronary artery calcification; 
CTCA, CT coronary angiography.








Age (years), mean±SD 56.8±12.0 51.7±11.1 62.3±10.5 <0.0001
Male gender, N (%) 810 (46.2%) 360 (39.3%) 450 (53.7%) <0.0001
Hypertension, N (%) 564 (32.3%) 198 (21.6%) 366 (43.7%) <0.0001
Diabetes mellitus, N (%) 135 (7.7%) 40 (4.4%) 95 (11.3%) <0.0001
Obesity, N (%) 211 (12.0%) 98 (10.7%) 113 (13.5%) 0.0746
Smoking history, N (%) 462 (26.4%) 219 (23.9%) 243 (29.0%) 0.0162
Family history, N (%) 559 (31.9%) 300 (32.8%) 259 (30.9%) 0.3989
CAC, coronary artery calcification; N, number.
(figure 1), and 46.2% were men. 52.2% of patients had 
a zero CAC versus 47.8% with non-zero CAC scores 
(median score 57.4 Agatston units; IQR 8.2–221). Patients 
with no detectable CAC were statistically more likely to 
be younger, women and less likely to have hypertension, 
diabetes or have a positive smoking history (table 1).
A total of 289 patients did not undergo CTCA after 
CAC scoring (159 patients with a zero CAC and 130 with 
non-zero CAC). The decision to perform a CTCA after 
CAC scoring was in line with contemporaneous clinical 
guidelines and hospital protocol. The major reasons 
were first, a low pretest probability for CAD plus a zero 
CAC score (n=112), and second, extensive calcification 
on CAC scan thought likely to preclude CTCA analysis 
(n=88). CTCA was not performed in a further 89 patients 
because of difficult venous access, contrast allergy or 
patient preference. In addition, subjects with non-inter-
pretable CTCA scans (n=7) were excluded from the CAD 
extent analysis, but their calcium scores and clinical prog-
ress contributed to MACE and mortality estimates.
Of the 751 patients with a zero CAC in whom CTCA was 
performed, 674 (89.7%) had normal coronary arteries, 
63 (8.4%) had <50% stenosis and 14 (1.9%) had ≥50% 
stenosis (figure 2). In the non-zero CAC cohort, of the 
706 patients who underwent CTCA, 9 (1.3%) had normal 
coronary arteries, 489 (69.3%) had <50% stenosis and 
208 (29.5%) had ≥50% stenosis.
In those with a zero CAC, there was no significant differ-
ence in the baseline risk factors in those with or without 
obstructive CAD (≥50% stenosis) with the exception of 
obesity and smoking history (table 2).
The negative predictive value of a zero CAC for 
excluding obstructive CAD (≥50% stenosis) was 98.1%. 
The sensitivity of this was 93.7% and the specificity was 
59.7%.
Follow-up and MACe
Patients were followed up for a median of 2.2 years (IQR 
1.8–3.7 years). The longest follow-up period was 7 years. 
Kaplan-Meier curves for MACE-free survival are presented 
in figure 3. The number of MACEs was 5 (0.6%) in the 
zero CAC cohort versus 17 (2%) in the non-zero CAC 
cohort. The annualised rate of MACE in the zero CAC 
cohort was 1.9 per 1000 person-years versus 7.4 per 1000 
person-years in the non-zero CAC cohort (table 3).
MACE in those with zero CAC were due to non-fatal 
myocardial infarction and/or non-elective revascularisa-
tion. None died of a coronary event. MACE occurred at 
a time interval of 13 days to 1.8 years after cardiac CT. 
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Figure 2 Prevalence of CAD following CTCA stratified according to CAC score. CAC, coronary artery calcification; CAD, 
coronary artery disease; CTCA, CT coronary angiography.
Table 2 Baseline characteristics of patients with a zero 






Age (years), mean±SD 51.73±11.24 54.49±8.13 0.3619
Male gender, N (%) 311 (42.2%) 8 (57.1%) 0.2624
Hypertension, N (%) 166 (22.5%) 5 (35.7%) 0.2436
Diabetes mellitus, N (%) 30 (4.1%) 1 (7.1%) 0.5670
Obesity, N (%) 71 (9.6%) 4 (28.6%) 0.0192
Smoking history, N (%) 165 (22.4%) 8 (57.1%) 0.0022
Family history, N (%) 230 (31.2%) 6 (42.9%) 0.3523
CAC, coronary artery calcification; CAD, coronary artery 
disease;CTCA, CT coronary angiography; N, number.
normal coronary arteries and one patient had ≥50% 
stenosis on CTCA. Of note, 1 patient who had a zero CAC 
score did not have CTCA and subsequently developed a 
non-ST elevation myocardial infarction and received 
non-elective revascularisation at 116 days post-scan.
In the unadjusted univariable analysis, there was 
moderate evidence that the survival distributions for the 
zero CAC versus the non-zero CAC cohort differed (HR 
3.8, 95% CI 1.4 to 10.3, p=0.009). After adjusting for the 
confounding factors age and gender, this difference was 
no longer statistically significant (HR 2.6, 95% CI 0.87 to 
7.9, p=0.09). After adjusting for age, gender plus cardio-
vascular risk factors, the HR for MACE among the zero 
CAC cohort vers non-zero CAC was 2.1 (95% CI 0.69 to 
6.5, p=0.19).
All-cause mortality
During follow-up, the incidence of all-cause mortality was 
three patients (0.17%) in the zero CAC cohort versus 20 
patients (1.1%) in the non-zero CAC cohort. Annualised 
rates of all-cause mortality for the zero CAC cohort were 
1.2 per 1000 person-years vers 8.7 per 1000 person-years 
in the non-zero CAC cohort.
In the unadjusted univariable analysis of all-cause 
mortality, there was evidence that the survival distribu-
tions for the zero CAC versus the non-zero CAC cohort 
differed (HR 7.6, 95% CI 2.3 to 26, p=0.001). After 
adjusting for age and gender, this was no longer statis-
tically significant (HR 2.5, 95% CI 0.67 to 9.1, p=0.18). 
After adjusting for age, gender plus cardiovascular risk 
factors, the HR for all-cause mortality among the zero 
CAC cohort versus non-zero CAC was 2.1 (95% CI 0.56 
to 8.0, p=0.27).
Composite endpoint: MACe and/or all-cause mortality
A composite endpoint comprising non-fatal myocardial 
infarction, non-elective revascularisation and/or all-cause 
mortality resulted in seven patients (0.40%) in the zero 
CAC cohort versus 36 patients (2.05%) in the non-zero 
CAC cohort with events. Following univariable analysis, 
there was evidence that the survival distributions for 
the zero CAC versus the non-zero CAC cohort differed 
(HR 5.8, 95% CI 2.6 to 13.0, p<0.0001). This difference 
remained statistically significant after adjusting for age 
and gender (HR 2.8, 95% CI 1.2 to 6.8, p=0.02). After 
adjusting for age, gender plus cardiovascular risk factors, 
this was no longer statistically significant (HR 2.3, 95% CI 
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Figure 3 Kaplan-Meier curves stratified according to CAC score (total population). CAC, coronary artery calcification
Table 3 Annualised MACE rates for all patients and 








CAC=0 915 (52.2%) 5 (0.55%) 1.92
CAC >0 838 (47.8%) 17 (2.03%) 7.37
All patients 1753 (100%) 22 (1.25%) 3.46
*Proportion of all patients.
†Proportion within each group.
.CAC, coronary artery calcification; MACE, major adverse cardiac 
event.
dIsCussIOn
Studies in asymptomatic individuals have shown that the 
absence of CAC is a reliable screening tool in the evalua-
tion for suspected CAD.3 9 However, there is uncertainty 
in the prevalence of CAD in symptomatic patients with a 
zero CAC score and in its longer-term prognostic impli-
cations.10
Prevalence of non-calcified CAd in symptomatic patients with 
a zero CAC
In this prospective cohort study of patients with stable 
chest pain, a zero calcium score was associated with a low 
rate of CAD, with 8.4% subjects having non-obstructive 
disease and only 1.9% found to have obstructive disease. 
Furthermore, a zero score had a high negative predictive 
value of 98.1% for excluding obstructive CAD.
Our results agree with similar studies in symptomatic 
patient populations. Among patients with zero CAC in 
the COroNary CT Angiography Evaluation For Clin-
ical Outcomes: An InteRnational Multicenter Registry 
(CONFIRM) registry, 13% had at least one <50% stenosis 
and 3.5% had at least one ≥50% stenosis.10 In a single-
centre prospective cohort study of 1114 patients, the 
prevalence of ≥50% stenosis was 4.3%.11 Negative predic-
tive values of 99.5%, 99% and 96%, respectively, have 
been quoted in the literature,10 12 13 close to our findings. 
The negative predictive value for zero CAC compares 
well with CTCA and stress imaging tests.14
Prognostic significance of a zero CAC
Over a medium-term follow-up, the incidence of MACE 
and all-cause mortality in our patients was lower in the 
zero CAC cohort than the non-zero CAC cohort. In multi-
variable survival analysis after adjusting for age, gender 
and cardiovascular risk factors, there was no difference 
in the prognosis between the two cohorts for both MACE 
and all-cause mortality end points (p=0.19 and p=0.27, 
respectively). However, the overall prognosis of stable 
angina in patients with zero CAC was good with an annu-
alised rate of MACE in the zero CAC cohort of 1.9 per 
1000 person-years.
We compared both MACE and all-cause mortality in 
patients with zero CAC versus non-zero CAC, whereas 
previous studies have focused only on all-cause mortality, 
and showed this to be 0.05% to 3.8% over a mean 
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incidence of MACE was found to be 1.3% over 2.8 years.11 
Importantly, these studies align with our findings that the 
overall prognosis of patients with a zero CAC is largely 
unaffected by the presence of non-calcified atheroma.12
CAC scoring versus CtCA
Although subjects with zero CAC had a good prognosis 
over during medium-term follow-up, 10.3% were found 
to have CAD on subsequent CTCA. Once identified, this 
group can benefit prognostically from medical therapy as 
demonstrated in the Scottish COmputed Tomography of 
the HEART Trial (SCOTHEART).15 16 The discovery of 
underlying CAD in those with zero calcium scores high-
lights the advantages of using CTCA in all subjects rather 
than having calcium scoring as a gatekeeper, as was the 
case in the previous version of the NICE CG95 guideline. 
CTCA without prior CAC scoring also lowers patient radi-
ation exposure.
study limitations
As an observational study, clinical data were obtained 
from the electronic records system and there may have 
been incomplete patient follow-up. We assumed that 
loss to follow-up would occur equally across the study 
cohort, thereby not unduly influencing results. As a 
single-centre study, our findings may not be applicable in 
other geographic regions. Finally, while we analysed the 
degree of luminal stenosis on CTCA, we did not take into 
account the impact of high-risk plaque features that are 
also known to have prognostic significance.17
COnClusIOn
A zero CAC score in patients with stable chest pain reli-
ably excludes obstructive CAD and is associated with an 
overall very good prognosis. However, CTCA provides 
further diagnostic and prognostic information, revealing 
underlying CAD in over 10% of patients. We now know 
that such patients should be treated with preventive 
medical therapy to improve their prognosis.
Contributors Contributors XW and EPVL contributed equally to the data collection, 
the statistical analysis and drafted the initial manuscript. JMT, NJHP and NKR 
contributed to the data collection. HP advised on the statistical analysis. JHFR, JB, 
MW, JMT and DG planned the study and JHFR is the study guarantor.
Funding JHFR is part-supported by the National Institute of Health Research (NIHR) 
Cambridge Biomedical Research Centre, the Higher Education Funding Council for 
England, the British Heart Foundation, the EPSRC and the Wellcome Trust. EPVL 
is funded by the Frank Edward Elmore Fund and the Medical Research Council’s 
Doctoral Training Partnership. JMT is supported by the Wellcome Trust.
Competing interests None declared.
Patient consent for publication Not required.
ethics approval The study was a planned clinical service evaluation and was 
carried out after favourable review by the hospital’s audit board.
Provenance and peer review Not commissioned; externally peer reviewed.
data sharing statement No additional data are available.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
RefeRences
 1. Budoff MJ, McClelland RL, Nasir K, et al. Cardiovascular events with 
absent or minimal coronary calcification: the multi-ethnic study of 
atherosclerosis (MESA). Am Heart J 2009;158:554–61.
 2. Moss AJ, Williams MC, Newby DE, et al. The updated NICE 
guidelines: cardiac CT as the first-line test for coronary artery 
disease. Curr Cardiovasc Imaging Rep 2017;10.
 3. Valenti V, ó Hartaigh B, Heo R, et al. A 15-year Warranty period for 
asymptomatic individuals without coronary artery calcium. JACC 
Cardiovasc Imaging 2015;8:900–9.
 4. Sarwar A, Shaw LJ, Shapiro MD, et al. Diagnostic and prognostic 
value of absence of coronary artery calcification. JACC Cardiovasc 
Imaging 2009;2:675–88.
 5. Hulten E, Bittencourt MS, Ghoshhajra B, et al. Incremental 
prognostic value of coronary artery calcium score versus CT 
angiography among symptomatic patients without known coronary 
artery disease. Atherosclerosis 2014;233:190–5.
 6. Rosen BD, Fernandes V, McClelland RL, et al. Relationship between 
baseline coronary calcium score and demonstration of coronary 
artery stenoses during follow-up MESA (multi-ethnic study of 
atherosclerosis). JACC Cardiovasc Imaging 2009;2:1175–83.
 7. National Institute for Health and Care Excellence. Chest pain of 
recent onset: assessment and diagnosis (clinical guidance 95), 2016; 
1–16. Available: https://www. nice. org. uk/ guidance/ cg95[Accessed 2 
Apr 2018].
 8. Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of 
coronary artery calcium using ultrafast computed tomography. J Am 
Coll Cardiol 1990;15:827–32.
 9. Blaha M, Budoff MJ, Shaw LJ, et al. Absence of coronary artery 
calcification and all-cause mortality. JACC Cardiovasc Imaging 
2009;2:692–700.
 10. Villines TC, Hulten EA, Shaw LJ, et al. Prevalence and severity of 
coronary artery disease and adverse events among symptomatic 
patients with coronary artery calcification scores of zero undergoing 
coronary computed tomography angiography. J Am Coll Cardiol 
2011;58:2533–40.
 11. Kim YJ, Hur J, Lee H-J, et al. Meaning of zero coronary calcium 
score in symptomatic patients referred for coronary computed 
tomographic angiography. Eur Heart J Cardiovasc Imaging 
2012;13:776–85.
 12. Mittal TK, Pottle A, Nicol E, et al. Prevalence of obstructive coronary 
artery disease and prognosis in patients with stable symptoms 
and a zero-coronary calcium score. Eur Hear J Cardiovasc Imaging 
2017;18:922–9.
 13. Abdool MA, Ashrafi R, Davies M, et al. A UK cardiac centre 
experience of low-risk, stable chest pain patients with calcium score 
of zero. Br J Cardiol 2014;21.
 14. Meijboom WB, Meijs MFL, Schuijf JD, et al. Diagnostic accuracy 
of 64-slice computed tomography coronary angiography: a 
prospective, multicenter, multivendor study. J Am Coll Cardiol 
2008;52:2135–44.
 15. Adamson PD, Hunter A, Williams MC, et al. Diagnostic and 
prognostic benefits of computed tomography coronary angiography 
using the 2016 National Institute for health and care excellence 
guidance within a randomised trial. Heart 2018;104:207–14.
 16. The SCOT-HEART Investigators. Coronary CT angiography and 
5-year risk of myocardial infarction. N Engl J Med 2018;379:924–33.
 17. Motoyama S, Ito H, Sarai M, et al. Plaque characterization by 
coronary computed tomography angiography and the likelihood 





ay 2019 by guest. Protected by copyright.
http://openheart.bmj.com/
O
pen Heart: first published as 10.1136/openhrt-2018-000945 on 11 April 2019. Downloaded from
 
